Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ELVN
Upturn stock ratingUpturn stock rating

Enliven Therapeutics Inc. (ELVN)

Upturn stock ratingUpturn stock rating
$20.06
Last Close (24-hour delay)
Profit since last BUY-7.56%
upturn advisory
WEAK BUY
BUY since 14 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ELVN (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

8 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $40

1 Year Target Price $40

Analysts Price Target For last 52 week
$40Target price
Low$13.3
Current$20.06
high$30.03

Analysis of Past Performance

Type Stock
Historic Profit -46.76%
Avg. Invested days 23
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.22B USD
Price to earnings Ratio -
1Y Target Price 40
Price to earnings Ratio -
1Y Target Price 40
Volume (30-day avg) 8
Beta 0.95
52 Weeks Range 13.30 - 30.03
Updated Date 06/30/2025
52 Weeks Range 13.30 - 30.03
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.92

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -21.36%
Return on Equity (TTM) -31.3%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 930138364
Price to Sales(TTM) -
Enterprise Value 930138364
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -6.28
Shares Outstanding 58990200
Shares Floating 30393498
Shares Outstanding 58990200
Shares Floating 30393498
Percent Insiders 4.75
Percent Institutions 88.34

Analyst Ratings

Rating 3
Target Price 40
Buy 1
Strong Buy 7
Buy 1
Strong Buy 7
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Enliven Therapeutics Inc.

stock logo

Company Overview

overview logo History and Background

Enliven Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule kinase inhibitors for the treatment of cancer. Founded in 2018, the company aims to address unmet needs in specific cancer patient populations. The company went public in 2023.

business area logo Core Business Areas

  • Precision Oncology: Enliven focuses on developing targeted therapies that address specific genetic drivers of cancer. Their lead product candidates are designed to selectively inhibit specific kinases implicated in cancer growth and resistance.
  • Small Molecule Drug Development: Enliven's expertise lies in the discovery and development of small molecule inhibitors, which are designed to be orally bioavailable and target intracellular kinases.

leadership logo Leadership and Structure

The leadership team consists of experienced professionals in drug development, oncology, and finance. The company structure includes research and development, clinical operations, and business development functions.

Top Products and Market Share

overview logo Key Offerings

  • ELVN-3231: A highly selective, potent, and orally bioavailable small molecule inhibitor of the mutant isocitrate dehydrogenase 1 (mIDH1) enzyme. Currently in clinical development. Competitors include Agios Pharmaceuticals (acquired by Servier) with Tibsovo.
  • ELVN-3106: A potent and selective small molecule inhibitor of the EGFR exon 20 insertion mutations. Currently in clinical development. Competitors include TAKEDA with EXKIVITY (mobocertinib).

Market Dynamics

industry overview logo Industry Overview

The oncology market is a large and growing market, driven by an aging population, advances in cancer diagnostics, and the development of new targeted therapies. Precision oncology is a rapidly evolving field, with increasing emphasis on personalized medicine based on genetic profiling of tumors.

Positioning

Enliven Therapeutics is positioned as a precision oncology company focused on developing innovative kinase inhibitors for specific cancer targets. Their competitive advantage lies in their expertise in small molecule drug development and their focus on addressing unmet needs in genetically defined cancer populations.

Total Addressable Market (TAM)

The global oncology market is expected to reach over $500 billion by 2030. Enliven is positioned to capture a share of this market by developing targeted therapies for specific cancer subtypes.

Upturn SWOT Analysis

Strengths

  • Strong scientific expertise in kinase inhibitor development
  • Focus on precision oncology and targeted therapies
  • Lead product candidates with promising preclinical and clinical data
  • Experienced management team
  • Strong cash position from IPO

Weaknesses

  • Early-stage clinical development, high risk of failure
  • Reliance on a limited number of product candidates
  • Competition from larger pharmaceutical companies
  • High cash burn rate

Opportunities

  • Potential for accelerated approval pathways for targeted therapies
  • Expansion of pipeline through internal research and development or acquisitions
  • Partnerships with larger pharmaceutical companies for clinical development and commercialization
  • Expanding market for precision oncology

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from existing and emerging therapies
  • Patent challenges
  • Economic downturn affecting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • AGIO
  • TAK
  • MRTX

Competitive Landscape

Enliven Therapeutics is a smaller player in a competitive market. Their advantages include their focus on specific cancer targets and their expertise in small molecule drug development. However, they face competition from larger pharmaceutical companies with more resources and established products.

Growth Trajectory and Initiatives

Historical Growth: As a recently IPO'd company, historical growth is primarily defined by preclinical and early clinical development progress.

Future Projections: Future growth is dependent on successful clinical development and regulatory approval of their lead product candidates. Analyst estimates will vary based on perceived probability of success.

Recent Initiatives: Focus on advancing ELVN-3231 and ELVN-3106 through clinical trials, expanding pipeline through internal research and development, and building strategic partnerships.

Summary

Enliven Therapeutics is an early-stage biopharmaceutical company with a focus on precision oncology. The company has promising lead product candidates in clinical development. However, it faces significant risks associated with clinical trials, regulatory hurdles, and competition from larger pharmaceutical companies. A strong cash position provides runway, but its future success hinges on clinical data and partnerships.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Enliven Therapeutics Investor Relations
  • SEC Filings
  • Company Press Releases
  • Analyst Reports

Disclaimers:

This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investors should conduct their own due diligence before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Enliven Therapeutics Inc.

Exchange NASDAQ
Headquaters Boulder, CO, United States
IPO Launch date 2020-03-12
Co-Founder, CEO, Secretary & Director Mr. Samuel S. Kintz M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 65
Full time employees 65

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.